← All publications

In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing

Tjin Tham Sjin R, Lee K, Walter AO, … Singh J · Mol Cancer Ther 2014 · Mol Cancer Ther 13(6):1468-79

EGFR (Tyr), Covalent Inhibitors Tyrosine kinase Covalent inhibitor kineticsInhibitor discovery & SAR PhosphoSens

Read the paper View on PubMed

More publications on EGFR

Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations

Junttila MR, Repellin CE, Salaniwal S, … Friedman LS · Cancer Res 2026

Structural Studies of Fourth-Generation EGFR Inhibitors Reveal Insights into Selective T790M and C797S Targeting

Damghani T, Song S, Lin KS, … Heppner DE · ACS Med Chem Lett 2026

TAS3351 is a brain penetrable EGFR-TKI that overcomes T790M and C797S resistant mutations

Kasuga H, Kataoka Y, Yamamoto F, … Mizuarai S · Commun Med (Lond) 2026

Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies

Stewart HL, Bordoni C, Jennings CE, … Waring MJ · J Med Chem 2025

Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer

Milgram BC, Borrelli DR, Brooijmans N, … Guzman-Perez A · J Med Chem 2025

Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent binding

Morese PA, Ahmad A, Martin MP, … Waring MJ · Commun Chem 2025

AssayQuant Technologies logo

 

 

260 Cedar Hill Street
Marlboro MA 01752

Phone: +1 (508) 804-3155

      

© 2026 AssayQuant Technologies, Inc. - All Rights Reserved - Privacy Policy - Terms & Conditions - FCOI